P

Parabilis Medicines

Develops first-in-class cancer therapeutics

Director – Discovery DMPK

Biology & BiotechConfirmed live in the last 24 hours
Full-timeCambridge, MA, USA

About the Job

Requirements

  • PhD or equivalent in DMPK, pharmacology, biology, chemistry, pharmaceutical sciences, or a related discipline with 10+ years of relevant industry experience, or an MS with 13+ years of relevant experience.
  • Demonstrated track record of leading DMPK strategy across multiple discovery and development programs, including experience advancing compounds through lead optimization, development candidate nomination, and IND-enabling activities.
  • Deep understanding of peptide and small molecule ADME/PK principles, with the ability to apply DMPK concepts to complex or emerging modalities.
  • Strong understanding of human translation, including PK/PD relationships, human PK and dose projection, transporter/DDI assessment, and exposure-response relationships.
  • Proficiency with Phoenix WinNonlin and R for PK analysis, data interpretation, and PK/PD reporting.
  • Significant experience selecting and overseeing external CRO partners, including study strategy, technical oversight, troubleshooting, timelines, budgets, and data quality.
  • Demonstrated ability to provide expert-level DMPK guidance for regulatory submissions, including INDs, Investigator Brochures, briefing documents, and responses to regulatory authorities.
  • Strong scientific leadership and influencing skills, with demonstrated ability to drive decisions across medicinal chemistry, pharmacology, toxicology, clinical pharmacology, and other cross-functional stakeholders without relying on direct authority.
  • Demonstrated ability to utilize AI tools in day-to-day scientific work.
  • Able to work on-site and participate regularly in in-person project and leadership meetings.

Responsibilities

  • Provide strategic leadership for peptide DMPK across multiple discovery programs, establishing ADME strategy and ensuring alignment with program milestones, development objectives, and broader portfolio priorities.
  • Lead the design, interpretation, and integration of in vitro and in vivo ADME/PK studies to drive lead optimization, development candidate nomination, and progression into IND-enabling development.
  • Serve as a DMPK subject matter expert and strategic partner to medicinal chemistry, pharmacology, toxicology, and other cross-functional functions, integrating DMPK data to influence chemical design and prioritize novel chemical matter with favorable drug-like and translational properties.
  • Identify and proactively address key DMPK risks, knowledge gaps, and development challenges, establishing fit-for-purpose strategies to enable program progression.
  • Provide scientific oversight of external CROs and partners, ensuring high-quality execution of DMPK studies within program timelines and budgets.
  • Present DMPK strategies, integrated data assessments, human translation considerations, and risk/benefit recommendations to project teams and senior leadership to inform key investment and development decisions.
  • Provide DMPK leadership for regulatory strategy and submissions, including IND/NDA, Investigator Brochures, briefing documents, and responses to regulatory authorities.
  • Co-lead the development and implementation of AI-enabled DMPK workflows and digital solutions to streamline operations, accelerate data analysis and integration, and enable faster, data-driven decision-making across discovery and development programs.
  • Build and advance DMPK capabilities in bioanalysis and peptide transporter sciences by strategically leveraging internal expertise, external partners, CROs, and emerging technologies to address program needs and strengthen organizational capabilities.
  • Mentor and provide scientific guidance to junior scientists while contributing to the continued development of DMPK capabilities, technologies, and best practices across the organization.

Desired Qualifications

  • Experience with biologics.
  • Hands-on modeling or regulated bioanalysis experience.
  • Advanced or innovative application of AI to DMPK analysis, data interpretation, or scientific workflows.

About the Company

Parabilis Medicines

Develops first-in-class cancer therapeutics

Parabilis Medicines advances drug discovery for cancer by developing a novel class of therapeutics called Helicon therapeutics. Its lead candidate, FOG-001, is a first-in-class inhibitor that blocks TCF-mediated β-catenin signaling, aimed at targeting common yet hard-to-treat drivers of cancer. The company uses integrated technologies to speed up discovery and scale development from research through potential commercialization. Compared with peers, Parabilis emphasizes a unique mechanism (TCF/β-catenin pathway inhibition) and a platform-driven approach designed to accelerate progression toward precision cancer therapies. The goal is to shape the future of precision medicine by delivering new treatments for previously untreatable diseases and advancing into clinical development with impactful candidates.

Company size
201-500
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2016

Recently Posted Jobs

Explore more opportunities at Parabilis Medicines

See more jobs